|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 亚太地区慢性乙型肝炎治疗共识(2012最新版)显示文摘自2008年至今,有大量关于慢性HBV感染的自然史和治疗的最新数据不断涌现。其中包括慢性HBV感染的无症状感染者,以社区为基础的队列研究,HBV基因型的作用,非药物诱导的自然HBV变异型毒株,无创性肝纤维化评估方法的应用,HBsAg定量在临床中的应用,更有效的新治疗药物和新治疗方案等等。来自亚太地区的专家审查和评估了相关数据,并共同商讨了近年来报道的最有意义的发现,基于此,对2008年版的亚太地区慢性乙型肝炎治疗共识进行修订,同时对2008年版治疗指南定义的关键词组进行了修订。修订后的指南包括以下几方面内容:一般治疗,肝纤维化评价适应证,何时开始治疗或停药,初始抗病毒治疗药物的选择,如何监测治疗中和治疗后的患者。关于特殊人群的治疗建议中包括了对妊娠妇女,已发生耐药,合并其他病毒感染,肝功能失代偿,接受免疫抑制治疗、化疗,肝移植或肝细胞癌患者的具体治疗建议。 | 廖运范 Jia-HorngKao Teerha Piratvisuth Henry Lik Yuen Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Wan-Long Chuang Laurentius A.Lesmana Jose D.Sollano Dong-Jin Suh Masao Omata 刘颖 徐莹 李芸 黄祖雄 樊蓉 李小溪 吕国涛 周彬 孙剑 侯金林 | 2012 | 临床肝胆病杂志2012，28，8： | 182 |
| 2 | Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load显示文摘AIM: To characterize the peripheral T-cell subpopulation profiles and their correlation with hepatitis B virus (HBV) replication in different clinical stages of chronic HBV infection.METHODS: A total of 422 patients with chronic HBV infection were enrolled in this study. The patients were divided into three stages: immune-tolerant stage, immune active stage, and immune-inactive carrier stage. Composition of peripheral T-cell subpopulations was determined by flow cytometry. HBV markers were detected by enzyme-linked immunosorbent assay. SerumHBV DNA load was assessed by quantitative real-time polymerase chain reaction.RESULTS: CD8+ T-cells were significantly higher in patients at the immune-tolerant stage than in patients at the immune-active and -inactive carrier stages (36.87 ± 7.58 vs 34.37 ± 9.07, 36.87 ± 7.58 vs 28.09 ± 5.64, P < 0.001). The peripheral blood in patients at the immune-tolerant and immune active stages contained more CD8+ T-cells than CD4+ T-cells (36.87 ± 7.58 vs 30.23 ± 6.35, 34.37 ± 9.07 vs 30.92 ± 7.40, P < 0.01), whereas the peripheral blood in patients at the immune-inactive carrier stage and in normal controls contained less CD8+ T-cells than CD4+ T-cells (28.09 ± 5.64 vs 36.85 ± 6.06, 24.02 ± 4.35 vs 38.94 ± 3.39, P < 0.01). ANOVA linear trend test showed that CD8+ T-cells were signif icantly increased in patients with a high viral load (39.41 ± 7.36, 33.83 ± 7.50, 31.81 ± 5.95 and 26.89 ± 5.71, P < 0.001), while CD4+ T-cells were signif icantly increased in patients with a low HBV DNA load (37.45 ± 6.14, 33.33 ± 5.61, 31.58 ± 6.99 and 27.56 ± 5.49, P < 0.001). Multiple regression analysis displayed that log copies of HBV DNA still maintained its highly signif icant coefficients for T-cell subpopulations, and was the strongest predictors for variations in CD3+, CD4+ and CD8+ cells and CD4+/CD8+ ratio after adjustment for age at HBV-infection, maternal HBV-infection status, presence of hepatitis B e antigen and HBV mutation.CONCLUSION: Differences in peripheral T-cell subpopulation profi les can be found in different clinical stages of chronic HBV infection. T-cell impairment is signifi cantly associated with HBV load. | Jing You Lin Zhuang Yi-Feng Zhang Hong-Ying Chen Hutcha Sriplung Alan Geater Virasakdi Chongsuvivatwong Teerha Piratvisuth Edward McNeil Lan Yu Bao-Zhang Tang .lun-Hua Huang | 2009 | World Journal of Gastroenterology2009，15，27： | 39 |
| 3 | Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital显示文摘AIM To determine the clinical presentations,survival and prognostic factors of hepatocellularcarcinoma(HCC)in Southern Thailand.METHODS Retrospective analysis wasperformed on the 336 hepatocellular carcinomapatients treated at Songklanagarind hospitalbetween 1 January 1991 and 31 January 1999.RESULTS Of these 336 patients,276 weremales and 60 were females.The mean age was54.4 years.The common symptoms and signswere abdominal pain and hepatomegaly.Themost common presentation of tumor was adominant mass with daughter nodules.Portalvein involvement was found in 50% of total.Extrahepatic metastasis was found in 13%,andthe lung was the most common site.There were55.4% with evidence of cirrhosis and half ofthem were in Childs class B.HBsAg waspositive in 72.6%.Regarding Okuda’s tumorstaging,15%,61% and 24% were stage Ⅰ,Ⅱand Ⅲ,respectively.Overall median survivalwas 2.1 months(11.5,2.6 and 0.7 months forstage Ⅰ,Ⅱ and Ⅲ respectively).Treatments ofHCC improved patient survival(5.5 months vs1.6 months for untreated patients ).Mostcommon causes of death were hepatic failure.Using multivariate analysis,the prognostic factors identified were tumor staging,alpha-fetoprotein level above 10000μg·L-1extrahepatic metastasis,portal vein thrombosisand treatment.CONCLUSION HCC in Thailand is a fataldisease with poor outcome due to latepresentation and high prevalence of livercirrhosis.Early detection and propermanagement may improve outcome. | Pasiri Sithinamsuwan Teerha Piratvisuth Wiwatana Tanomkiat Nualta Apakupakul Surat Tongyoo | 2000 | World Journal of Gastroenterology2000，6，3： | 19 |
| 4 | Comprehensive review of telbivudine in pregnant women with chronic hepatitis B显示文摘AIM:To achieve an evidence-based conclusion regarding the safety and efficacy of telbivudine during pregnancy.METHODS:A pooled analysis of data from a literature search reported 1739 pregnancy outcomes(1673 live births)from 1725 non-overlapping pregnant women treated with telbivudine.The prevalence of live birth defects(3.6/1000)was similar to that of the nonantiviral controls(3.0/1000)and not increased as compared with overall prevalence(14.5 to 60/1000).No target organ toxicity was identified.The prevalence of spontaneous abortion in pregnant women treated with telbivudine(4.2/1000)was not increased compared with the overall prevalence(16/1000).The mother-to-child transmission rate was significantly reduced in pregnant women treated with telbivudine(0.70%)compared to those treated with the non-antiviral controls(11.9%;P<0.0001)or compared to the historical rates of hepatitis B virus(HBV)-infected population without antiviral treatment(10%-15%).RESULTS:Cumulatively 489 pregnancy cases have been reported in the telbivudine pharmacovigilance database(with a cut-off date 31 August 2014),of those,308 had known pregnancy outcomes with 249 cases of live births(239 cases of live birth without congenital anomaly and 10 cases of live birth with congenital anomaly).In the latest antiretroviral pregnancy registry report(1 January 1989 through 31 January 2015)of27 patients exposed to telbivudine during pregnancy(18,6 and 3 during first,second and third trimester,respectively)19 live births were reported and there were no cases of birth defects reported.CONCLUSION:Telbivudine treatment during pregnancy presents a favorable safety profile without increased rates of live birth defects,spontaneous abortion or elective termination,or fetal/neonatal toxicity.Exposure to telbivudine in the first,second and third trimester of pregnancy has been shown to significantly reduce the risk of HBV transmission from mother to child on the basis of standard immune prophylaxis procedure. | Teerha Piratvisuth Guo Rong Han Stanislas Pol Yuhong Dong Aldo Trylesinski | 2016 | World Journal of Hepatology2016，8，9： | 13 |
| 5 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update显示文摘 | Yun-Fan Liaw Nancy Leung Jia-Horng Kao Teerha Piratvisuth Edward Gane Kwang-Hyub Han Richard Guan George K. K. Lau Stephen Locarnini | 2008 | Hepatology International2008，，3： | 10 |
| 6 | Liver biopsy:complications and risk factors显示文摘INTRODUCTIONPercutaneousliverbiopsyisahelpfuldiagnosticprocedurewhichhasbeenusedfor100years[1-3].Althoughultrasonography,comp... | Pornpen Thampanitchawong and Teerha Piratvisuth | 1999 | World Journal of Gastroenterology1999，5，4： | 8 |
| 7 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update显示文摘 | Yun-Fan Liaw Nancy Leung Jia-Horng Kao Teerha Piratvisuth Edward Gane Kwang-Hyub Han Richard Guan George K. K. Lau Stephen Locarnini | 2008 | Hepatology International2008，，3： | 7 |
| 8 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius Lesmana Jose | 2012 | Hepatology International2012，，3： | 6 |
| 9 | Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report显示文摘 | Henry Lik-Yuen Chan Alex Thompson Michelle Martinot-Peignoux Teerha Piratvisuth Markus Cornberg Maurizia Rossana Brunetto Hans L. Tillmann Jia-Horng Kao Ji-Dong Jia Heiner Wedemeyer Stephen Locarnini Harry L.A. Janssen Patrick Marcellin | 2011 | Journal of Hepatology2011，，5： | 5 |
| 10 | 聚乙二醇干扰素α-2a、拉米夫定以及两者联合治疗HBeAg阳性的慢性乙型肝炎 | Lau G.K.K. Piratvisuth T. 李明 | 2005 | 世界核心医学期刊文摘(胃肠病学分册)2005，0，11： | 5 |
| 11 | Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions显示文摘 | Sang Hoon Ahn Henry L. Y. Chan Pei-Jer Chen Jun Cheng Mahesh K. Goenka Jinlin Hou Seng Gee Lim Masao Omata Teerha Piratvisuth Qing Xie Hyung Joon Yim Man-Fung Yuen | 2010 | Hepatology International2010，，1： | 3 |
| 12 | Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment‐na?ve patients with HBV‐related decompensated cirrhosis显示文摘 | H. L.Y. Chan Y. C. Chen E. J. Gane S. K. Sarin D. J. Suh T. Piratvisuth B. Prabhakar S. G. Hwang G. Choudhuri R. Safadi T. Tanwandee A. Chutaputti C. Yurdaydin W. Bao C. Avila A. Trylesinski | 2012 | Journal of Viral Hepatitis2012，，10： | 3 |
| 13 | Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update显示文摘 | Yun-Fan Liaw Jia-Horng Kao Teerha Piratvisuth Henry Lik Yuen Chan Rong-Nan Chien Chun-Jen Liu Ed Gane Stephen Locarnini Seng-Gee Lim Kwang-Hyub Han Deepak Amarapurkar Graham Cooksley Wasim Jafri Rosmawati Mohamed Jin-Lin Hou Wan-Long Chuang Laurentius A. | 2012 | Hepatology International2012，，4： | 2 |
| 14 | Optimal management of HBV infection during pregnancy显示文摘 | Teerha Piratvisuth | 2013 | Liver Int2013，，： | 2 |
| 15 | Peginterferon alfa-2a.lamivudine,and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | | 0，，： | 2 |
| 16 | Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients显示文摘 | Teerha Piratvisuth Patrick Marcellin Matei Popescu Hans-Peter Kapprell Vivien Rothe Zhi-Meng Lu | 2013 | Hepatology International2013，，2： | 2 |
| 17 | Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a显示文摘 | Patrick Marcellin Ferruccio Bonino George K.K. Lau Patrizia Farci Cihan Yurdaydin Teerha Piratvisuth Rui Jin Selim Gurel Zhi-Meng Lu Jian Wu Matei Popescu Stephanos Hadziyannis | 2009 | Gastroenterology2009，，7： | 2 |
| 18 | Reviews for APASL guidelines: immunomodulator thera- py of chronic hepatitis B 显示文摘 | Piratvisuth T | 2008 | Hepatol Int2008，2，2： | 1 |
| 19 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update显示文摘 | Yun-Fan Liaw Nancy Leung Jia-Horng Kao Teerha Piratvisuth Edward Gane Kwang-Hyub Han Richard Guan George K. K. Lau Stephen Locarnini | 2008 | Hepatology International2008，，3： | 1 |
| 20 | Peginterferon a-2a (40 kDa) : an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B 显示文摘 | Cooksley WG Piratvisuth T Lee SD | 2003 | J Viral Hepat2003，10，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员